Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Lung symbols : Azn save search
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Published: 2024-03-18 (Crawled : 13:30) - biospace.com/
ILMN | $122.74 -1.38% -1.4% 1.2M
|
Health Technology
|
| O: 0.51%
H: 2.49%
C: 1.37%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.45%
H: 0.55%
C: -0.24%
lung test cancer risk study
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $65.26 -4.38% 5.9K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-02-19 (Crawled : 09:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
| Email alert
Add to watchlist
lung license cancer cell application advanced
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.17%
H: 0.09%
C: -2.76%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 33.84%
H: 1.01%
C: -15.3%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.76%
H: 0.77%
C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Published: 2023-12-06 (Crawled : 22:00) - biospace.com/
ILMN | $122.74 -1.38% -1.4% 1.2M
|
Health Technology
|
| O: 1.4%
H: 3.94%
C: 0.58%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.73%
H: 0.06%
C: -1.38%
america lung conference test cancer
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Published: 2023-10-23 (Crawled : 19:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
lung cancer cell trial
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
Published: 2023-09-11 (Crawled : 19:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
tagrisso lung cancer trial plus
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
Published: 2023-09-11 (Crawled : 13:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
enhertu lung cancer tumor trial
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Published: 2023-09-11 (Crawled : 11:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
enhertu lung her2 cancer tumor trial
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Published: 2023-07-03 (Crawled : 08:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -6.26%
H: 0.33%
C: -2.74%
lung cancer cell trial
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2023: Increasing Prevalence of Lung Disease Drives Growth
Published: 2023-06-28 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 1.75%
H: 0.06%
C: 0.06%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 1.06%
H: 0.72%
C: 0.72%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.98%
H: 0.0%
C: -0.47%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.85%
C: 0.76%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -1.21%
H: 1.17%
C: 0.91%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.54%
H: 0.78%
C: 0.59%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.86%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.83%
H: 0.89%
C: 0.68%
lung disease report treatment global growth market
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.39%
H: 0.78%
C: 0.45%
lung cancer cell tumor trial
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.34%
H: 0.21%
C: -2.03%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 1.12%
H: 2.16%
C: -10.76%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.44%
H: 0.03%
C: -1.94%
reqorsa lung approval review cancer cell expansion trial
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: -0.02%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 3.65%
H: 7.04%
C: 1.02%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.06%
H: 0.48%
C: -0.04%
reqorsa lung asco positive cancer cell meeting trial therapy
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
Published: 2023-01-30 (Crawled : 14:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.3%
H: 0.06%
C: -0.81%
lung trial cancer initiated
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 16:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.49%
H: 1.65%
C: 0.94%
lung biomarker cancer study
Extensive Stage Small Cell Lung Cancer Global Market Report 2022: Need of Potential Treatments to Improve Quality of Life Drives Sector
Published: 2022-12-22 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.06%
H: 1.27%
C: 0.93%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.04%
H: 0.32%
C: 0.31%
lung global report life potential cancer market
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -1.61%
H: 1.82%
C: 1.82%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 2.34%
H: 5.98%
C: -0.85%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.76%
H: 1.04%
C: 0.47%
reqorsa lung trial approval review cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.